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management
There are few conditions where treatment and outlook have
improved so steadily and impressively, over so long a
period, as cystic fibrosis (CF). Since the first clear
description of the disease by Dorothy Andersen in 1938
(1), there has been a steady improvement in prognosis,
particularly marked over the past 10 to 15 years. The
outlook has improved from almost inevitable death in early
childhood to the present median survival of over 30 years
(2) and a predicted survival of over 40 years (3,4). An infant
with CF born today, diagnosed before chronic pulmonary
infection is established, should, with modern treatment,
have few, if any, chronic respiratory symptoms for many
years, avoiding chronic respiratory infection and the
inevitable associated decline in pulmonary function (5,6).
Although in many countries the outlook remained poor
until the mid 1970s, some clinicians realized that chronic
pulmonary infection and the inevitable respiratory failure
which followed were not inevitable and could be delayed or
minimized (7,8,9,10).
In 1974, Crozier, who started the Toronto clinic, in an
article Cystic fibrosis: a not so fatal disease advised that
‘there should be regular detailed assessment of the patient
with attempts to return to normal as far as possible’ (8).
Over recent years his advice has been a guiding principle of
management employed by an increasing number of
clinicians (11).
ESTABLISHMENT OF CF CENTRES
The remarkable scientific advances of the 1980s, from the
demonstration of chloride impermeability of the sweat0954-6111/00/070632+09 $35?00/0gland (12) to the identification of the CF gene in 1989
(13,14,15) have not, as yet, had a significant influence on
treatment. The improved outlook has been due entirely to
better conventional treatment that has been developed at
CF centres. The development of CF centres, where medical,
paramedical, nursing and laboratory sta gain experience
in management of the disease, has been central to the
progress made (16,17).
The more eective treatment of Pseudomonas aeruginosa
infection has been central to the increased survival, and is
repeatedly stressed by the authors of this review. Nebulized
Colomycin (Pharmax, Bexley, U.K.) (colistin), both to
eradicate early P. aeruginosa infection either alone (18) or
with oral ciprofloxacin (19,20) and to stabilize chronic
infection (21), has been a central component of the modern
treatment package in most European clinics.
The improved condition and survival of people with CF
has undoubtedly paralleled the increased use of antibiotics
and improved nutrition achieved by aggressive nutritional
support and the more eective acid resistant enzymes. It is
important to stress that all these improvements have been
introduced and evaluated at CF centres where the sta has
the opportunity of treating large numbers of patients.
GROWTH OF SHARED CARE
The essential requirement for a CF centre is an adequate
number of patients—usually a minimum of 50 on full care
at the clinic. Constantly being faced with the diverse
problems presented by large numbers of CF patients causes
the CF centre sta to explore ways in which treatment of
various aspects of the disease can be improved. In addition,
the most ecient and acceptable methods of giving new
treatments can be developed and tested if there are# 2000 HARCOURT PUBLISHERS LTD
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antibiotics, intravenous antibiotics, regular 3 monthly
i.v. (intravenous) antibiotics and enteral nutrition, to
mention only a few of the significant components of
modern care.
When the details of monitoring and treatment have been
established, much of the treatment can often be given by
those with fewer CF patients working in smaller general
hospitals. There is a move towards this so-called ‘shared
care’ in the U.K. for children although it is important that
all CF patients are known to and periodically reviewed by
the sta of a large specialist CF centre. Adults with CF are
advised to attend specialist CF centres in view of the
increasingly complex treatment they require.
MORE AGGRESSIVE TREATMENT OF
INFECTIONS DELAYS THE ONSET OF
CHRONIC INFECTION AND PROLONGS
LIFE
Previous studies showed that patients attending CF centres
in the U.S.A. where there was more frequent follow-up and
more frequent use of i.v. antibiotics had a much better
survival rate (22). The introduction of a policy of 3-monthly
i.v. antibiotics for patients chronically infected with P.
aeruginosa at the Copenhagen CF centre significantly
reduced the mortality of their patients (4). Also, the
reduction in the total number of chronically infected
patients has obviously had a major favourable eect on
survival (20).
Thus, the timing and intensity of treatment will
determine the fate of the CF patient. Prevention or early
treatment to eradicate P. aeruginosa infection is probably
the most important single measure that will improve the
long term prognosis, by preventing the patient moving from
a stable state to one of variable—but relentless—decline in
pulmonary function (23). When chronic infection becomes
established, aggressive treatment with regular 3-monthly
courses of i.v. antibiotics and with suppressive nebulized
antibiotics appears to be the best available treatment option
at present.
Colomycin is an interesting drug in the context of CF,
having been resurrected in the 1980s as P. aeruginosa
proved an increasing problem in children with CF. Many
were in excellent condition and without chronic infection,
Staphylococcus aureus having been successfully avoided or
treated (24), only to deteriorate following the onset of P.
aeruginosa infection. The drug’s activity against P. aerugi-
nosa, the very rare occurrence of resistance and the ability
to deliver it by nebulizer resulted in its introduction and
increasing use both to eradicate early P. aeruginosa and to
stabilize those who had acquired chronic infection. The
problems of resistance to other anti-pseudomonal anti-
biotics for the treatment of exacerbations has lead to an
increasing use of Colomycin by the intravenous route
(25,26).
In this article the various aspects of the use of the
Colomycin are reviewed by experienced microbiologists andclinicians who have been involved in the increasing and
successful use of the drug in the treatment of CF.
A radical change in therapy: C. Koch
P. aeruginosa has, over recent decades, become the most
frequent pathogen in the lower respiratory tract of patients
with CF. Chronic P. aeruginosa infection is now responsible
for the large majority of excess morbidity and mortality in
these patients since once established the organism cannot be
eradicated from the lower respiratory tract (27). Chronic P.
aeruginosa infection is, however, preceded by a period of
intermittent colonization which averages 12 months (28).
This prompted us to consider whether very early treatment
at the onset of intermittent colonization might prevent —or
least postpone—progression to chronic infection.
In 1986, therefore, we initiated a controlled trial
of the ecacy of 3 weeks of treatment with inhaled
Colomycin 106 IU twice daily and oral ciprofloxacin
250–750 mg (according to body weight), administered
whenever P. aeruginosa was isolated from lower
respiratory tract secretions at the routine monthly
visits to the clinic, in patients not chronically infected
(19). The choice of antibiotics was based upon studies
showing the clinical eect of these antibiotics in early
(18) and in chronically infected patients (18,21,29).
The study was designed as an open parallel trial
where 26 patients were randomized to treatment or no
treatment, and the outcome measure (endpoint) was
progression to chronic colonization/infection: this was
defined as presence of P. aeruginosa in monthly routine
specimens for 6 consecutive months, or a shorter period
accompanied by emergence of precipitating serum anti-
bodies against P. aeruginosa (30). During the trial period of
27 months, seven out of 12 untreated patients (58%)
became chronically colonized/infected with P. aeruginosa as
compared with two of the 14 treated patients (14%)
(P50?05) (19). Following these promising results a
modification of this strategy was introduced in our routine
treatment and this has been followed by a marked
reduction in the prevalence of chronic P. aeruginosa
infection in our patients (31).
It must be emphasized that the design of this early study
was quite simple and also easily applicable to our patients.
All patients are seen on a strict monthly basis and all visits
include sampling of lower respiratory secretions. The
patients/parents were familiar with our aggressive anti-
microbial treatment (‘intermittent prophylaxis’ with pre-
scription of antibiotics whenever pathogens were isolated,
even when asymptomatic, and were also familiar with
inhalation therapy (inhalation of b2-agonists and other
drugs). Furthermore, regular quantitation of anti-pseudo-
monal antibodies has been a routine measure since the
1960s (30).
The task that now lies ahead is to improve this early
treatment in order to protect all—not only 80%—of the
patients. We must be aware of the side eects such as the
acquisition of other and potentially more aggressive
Gram-negative organisms such as Burkholderia cepacia.
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very early aggressive treatment might be applied to other
Gram-negative organisms which may chronically infect the
lower respiratory tract (i.e. B. cepacia, Achromobacter
xyloxidans and others).
Recent studies have indicated that there may be
pharmacological means of correcting the cellular dysfunc-
tion(s) that lead to colonization of the respiratory tract in
CF with pathogenic microorganisms (32). We would
predict that only partial correction, but in combination
with our principle of close microbiological surveillance
coupled with early aggressive antimicrobial treatment,
might lead to complete protection of the patients against
chronic bronchopulmonary infections in the future. Life-
long absence of this devastating complication will drama-
tically improve quality of life and long-term survival in
patients with cystic fibrosis.
What makes Colomycin different?
P. A. Lambert
The polymyxins are a group of lipopeptide antibiotics
isolated from spore-forming soil bacterium, Bacillus poly-
myxa (33). Five major, chemically distinct members of the
group were recognized and designated as polymyxin A, B,
C, D and E. Colistin (Colomycin) was isolated in 1950 from
a related strain, Bacillus colistinus. It is identical to
polymyxin E, and has the characteristic polymyxin
structure comprising a cyclic heptapeptide joined to a
tripeptide chain with a single fatty acid substituent. For
parenteral and aerosol therapy colistin is used in the form
of the sodium salt of the negatively-charged derivative,
colistin sulphomethate, which is hydrolysed to the active,
positively charged colistin base after administration (34).
Colomycin is most notable for its activity towards P.
aeruginosa. Its spectrum of activity also includes Escher-
ichia coli, Enterobacter, Salmonella, Shigella and Klebsiella
spp but Proteus spp, B. cepacia, Bacteroides fragilis and
many Serratia marcescens strains are resistant to this drug
(35). Gram-positive bacteria are generally less sensitive than
those that are Gram-negative. This unusual spectrum of
activity results from its unique physical mechanism of
action which occurs in two stages: disruption of the
permeability barrier of the outer membrane followed by
penetration of the cytoplasmic membrane and destruction
of its integrity (36). The active form of the drug, the
positively charged colistin base, binds to the lipopolysac-
charide (LPS) component of the outer membrane of the
sensitive Gram-negative bacteria. The binding involves
interaction between the peptide ring of the colistin and
phosphate groups present on the lipid A and core region of
LPS. Colomycin displaces magnesium ions from the
phosphate groups, resulting in distortion of the outer
membrane structure and loss of the permeability barrier. P.
aeruginosa is particularly sensitive to Colomycin because its
LPS has a high phosphate content and associated
magnesium ions. Loss of the permeability barrier of the
outer membrane allows colistin to penetrate the cell wall tothe underlying cytoplasmic membrane, which is the
ultimate target for the lethal action of the antibiotic.
Insertion of colistin molecules between the phospholipid
and protein components of cell membranes results in loss of
membrane integrity, leakage of cytoplasmic constituents
and cell death. Colomycin therefore exerts a rapid, lethal
action upon sensitive bacteria.
The self-promoted uptake mechanism of Colomycin is
quite dierent from the uptake pathways used by other anti-
pseudomonal antibiotics. The quinolones and b-lactams
must cross the permeability barrier of the outer cytoplasmic
membrane to reach their enzyme targets in the cytoplasm
and cytoplasmic membrane respectively. They do not
damage the outer membrane to promote their own uptake
and must rely upon passive diusion through porin channels
to cross the cell envelope. Resistance to these agents can
result from alterations in porin composition and through
the action of eux pumps (37). Clinical resistance of P.
aeruginosa to Colomycin by these or other mechanisms is
very rare. The aminoglycosides do exert some damage on
the outer membrane, and, to some extent promote their own
uptake. However, unlike Colomycin, they require an active
transport process involving respiratory activity to cross the
cytoplasmic membrane and reach their ribosomal target site.
Aminoglycosides are therefore susceptible to resistance
through absence of the transport system (e.g. in anaerobes)
and through extrusion by eux pumps.
In lung infections associated with CF P. aeruginosa exists
in the form of microcolonies or adherent biofilms compris-
ing cells surrounded by a layer of alginate polysaccharide
attached to lung epithelial cells. Failure of antibiotics to
eradicate the organism in this intractable mode of growth is
due to the reduced growth rate of cells and restricted
penetration of antibiotics (38). The alginate layer eectively
protects the cells from phagocytic attack whilst LPS released
from the bacteria generates a frustrated macrophage response
which exacerbates the inflammatory conditions within the
lungs. The therapeutic benefit of colistin in CF could result
from its ability to kill slow-growing and non-growing cells in
the microcolonies. Furthermore, binding of LPS released from
the cells might also contribute to the treatment through
neutralization of its inflammatory action (39).
Colomycin—a constant in an
increasingly resistant world of
microorganisms: N. Høiby
When nebulized Colomycin was introduced in the Danish
CF Centre the decision was based on preliminary very
promising results from Littlewood et al. (18). Daily
inhalation therapy with Colomycin was employed to
further improve the ‘maintenance therapy = chronic
suppressive therapy’ in CF patients with chronic P.
aeruginosa infection (21). A few years earlier the centre
had experienced an epidemic caused by a multi-resistant
strain (40) with a high level of chromosomal b-lactamase
production and a high level of resistance to tobramycin
(41). To avoid further problems of resistance, Colomycin
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resistant P. aeruginosa did not occur in hospitals although
this drug had been used for many years, and in spite of the
fact that resistance can be easily induced in vitro (42,43).
Another reason for choosing Colomycin was its narrow
spectrum, which would probably induce only minor
changes in the normal flora of the mouth, the throat and
the gut. The prodrug nature of Colomycin would probably
further protect the normal flora, since the drug requires
hydrolytic activation leading to release of formaldehyde
and bisulphite. This is probably why selection of colistin-
resistant microorganisms such as Burkholderia spp. has not
been observed in the Danish CF Centre (44). Another
potential beneficial property of Colomycin is its ability to
neutralize bacterial lipopolysaccharides and their biological
eects and thereby functioning as an anti-endotoxin
reagent (45,46).
Colomycin inhalation has now been used for daily
maintenance therapy in a group of approximately 120
Danish CF patients with chronic P. aeruginosa lung
infection since 1987. During this period Colomycin
resistant strains have only been observed in 14 patients
(MIC 100–400 mgml71) whereas strains infecting other
CF patients remained sensitive (geometric mean of
MIC 2.4 mgml71). The following successful policy was
employed several times to get rid of such strains: the
use of nebulized Colomycin was stopped in each of these
patients specifically, and generally in the ward for
chronically P. aeruginosa infected CF patients for a period
of 6 months. This small problem of resistance to Colomycin
is remarkable in a CF centre where aggressive antibiotic
treatment has been used for 30 years and where selective
pressure of colistin is so intensive that resistance to
aminoglycosides, b-lactam antibiotics and fluoroquinolones
is common (40,41,47,4). Resistance to Colomycin, there-
fore, seems to develop more slowly than resistance to
tobramycin (48).
When 3-week courses of Colomycin inhalation in
combination with oral ciprofloxacin were introduced in
1991 to eradicate initial P. aeruginosa colonization
(19), resistance was not a matter of concern, since the
number of P. aeruginosa in the lungs was presumed to be
low during early colonization, which is generally only
accompanied by few discrete symptoms, if any (49). This
assumption has been supported by monthly bacteriological
data from all CF patients in the Danish CF Centre to date
(31,20), since the 20% treatment failures have not been
associated with resistance to the two drugs used but to
switch to chronic infection characterised by the mucoid
phenotype.
In conclusion, Colomycin has fulfilled the expectations as
to high ecacy and low resistance after more than 10 years
of use in the Danish CF Centre.
Impact of Colomycin on management
of adult CF patients: J. S. Elborn
The improved survival of patients with CF over the past
three decades has resulted in an increasing number ofpatients being cared for in Adult CF Clinics (2). One
component of treatment contributing to this improved
survival has been aggressive antibiotic treatment of
pulmonary infection, particularly in patients with chronic
P. aeruginosa infection (9).
The three major strategies to reduce lung injury are:
eradication of early P. aeruginosa infection with inhaled
and oral antibiotics at the time of first isolation; prompt
and aggressive i.v. antibiotic treatment of acute exacerba-
tions of pulmonary infections; and long-term inhaled
suppressive therapy for patients who are chronically
infected with P. aeruginosa. Colomycin has an important
role in each of these.
It is clear that early infection with P. aeruginosa can be
eradicated by nebulized Colomycin and oral ciprofloxacin
(19,20). This treatment is increasingly used in patients
attending the Adult CF Clinic as more adolescents are free
of P. aeruginosa when transferred to adult care. Intrave-
nous anti-pseudomonal antibiotics may also be valuable in
this situation but the combination of a nebulized and oral
drug has the advantage of allowing the adult patient to
remain at home and continue with normal activities (50).
Treating early infection and postponing chronic infection
with P. aeruginosa is important in reducing morbidity and
is likely to increase survival (5,6).
The treatment of pulmonary exacerbations in patients
chronically infected with P. aeruginosa is a second major
challenge in the management of adults with CF (51). Some
centres treat such patients with regular 3-monthly courses
of i.v. antibiotics though this approach is not conclusively
proven to be superior to treating exacerbations promptly
when required (51,52). Treatment of exacerbations usually
involves a b-lactam based antibiotic and an aminoglyco-
side. There is evidence of increasing resistance of P.
aeruginosa against many of the b-lactam and aminoglyco-
side antibiotics (53). This is most likely to be due to
antibiotic pressure. Colomycin, a polymyxin antibiotic, is a
dierent class from commonly used i.v. antibiotics and has
been shown to be of value in combination with other anti-
pseudomonal antibiotics in treating acute exacerbations
(25). Polymyxin antibiotics can be nephrotoxic, but studies
to date have shown that Colomycin has only a minimal
eect on renal function (25). Although most clinicians
would not use Colomycin as a first line i.v. antibiotic, it is a
valuable addition to the range of i.v. antibiotics currently
available.
The major use of Colomycin in adults in the U.K. and
Europe is as an aerosol for chronic suppressive therapy for
patients chronically infected with P. aeruginosa (21,54).
Once chronically infected, all patients should be encour-
aged to use regular inhaled Colomycin (21,55), although
it can be dicult to persuade patients with relatively
normal lung function who feel well and have few pul-
monary exacerbations to take regular nebulized treatment.
Compliance with Colomycin treatment is challenging to
many patients as it requires significant time for preparation
and nebulization twice daily. Some patients experience
tightness of the chest with the inhalations and some may
have a significant drop in FEV1 (56). This can usually be
overcome by the use of a bronchodilator prior to treatment.
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the Copenhagen Clinic of 3 months treatment with
Colomycin and ciprofloxacin for early P. aeruginosa
infection (20). Although there is limited evidence in terms
of medium and long-term outcome for this approach to
treatment, some studies do indicate improvement or
stabilization of lung function (21,54). Nebulized tobramy-
cin has also been shown to be of value as a chronic
suppressive treatment in patients with CF (57), although P.
aeruginosa resistance to tobramycin increases in some
patients (48). In vitro resistance of P. aeruginosa to
Colomycin is extremely rare, which is advantageous for a
drug used for chronic suppressive treatment of P.
aeruginosa, which frequently becomes resistant to other b-
lactam and aminoglycoside antibiotics.
Colomycin remains a valuable antibiotic in the treatment
of adult patients with cystic fibrosis. It has value as
treatment for early P. aeruginosa infections, for acute
exacerbations and chronic suppressive therapy. In general,
the drug is well tolerated and is likely to remain a useful
treatment for the foreseeable future.
The use of intravenous Colomycin:
S. P. Conway
Patients with CF are living longer with a mean age at death
in the U.K. now over 30 years of age (2). Today’s children
with CF are confidently expected to enjoy a near normal
lifespan (4). There are many reasons for this revolution in
CF care but our success is founded on optimal
application of three treatment modalities: i.v. antibiotics,
chest physiotherapy, and nutritional support. There
are three main reasons why we are using more of the
former. Although not accepted by all doctors, and
although based on comparison with a retrospective
control group, the Copenhagen data—showing
improved survival in patients with chronic P. aeruginosa
infection who receive elective 3-monthly courses of
intravenous anti-pseudomonal antibiotic therapy—has
stimulated many centres to copy the Danish lead (9).
Although a large number of patients remain in good health,
many others need frequent i.v. antibiotic treatments just to
maintain stability. A small proportion of patients on the
transplant waiting list are on a continuous programme of
rotating antibiotics. The inevitable consequence of in-
creased antibiotic use is increased bacterial resistance and
an increase in patient hypersensitivity reactions (53). No
new anti-pseudomonal antibiotics have been marketed
since meropenem in 1995. P. aeruginosa resistance to
Colomycin is very unusual (47,58,59) and hypersensitivity
reactions are rare. It was time to revisit this potentially
useful drug.
Colomycin suers from its reputation as a neurotoxic
and nephrotoxic drug. How much of this is real and how
much mythical? What do the toxicity data show? Fears of
increased serum creatinine and blood urea levels, acute
renal failure, acute tubular necrosis, paraesthesiae, muscle
weakness, dizziness, confusion, and respiratory insu-ciency secondary to neuromuscular blockade stem from
reports dating back 30 years or more (60–65). Such reports
of Colomycin induced adverse reactions were also variable
(63,65–67), did not refer to patients with CF, and reversed
when Colomycin treatment was stopped, even when large
doses had been used (60–62). Some patients had complex
underlying illness and the attribution of adverse clinical
events to Colomycin was probably not scientifically exact
(60).
Recent studies in patients with CF have confirmed the
safety of intravenous Colomycin. Southern et al. reported
on 62 courses in 22 patients without any neuro- or
nephrotoxic adverse eects (58). Bosso et al. documented
only one case of reversible renal toxicity and six minor
neurological events that did not necessitate withdrawal of
Colomycin in 21 treatment courses (68). In a large
prospective study of 71 treatment courses in our centre
we saw a significant rise in mean serum urea levels, but this
value remained within the normal laboratory range
[57?1mmol l71]. Four patients had abnormally high levels
at the end of treatment but showed values only marginally
above the normal upper limit, ranging from 7.3 to
7.6mmol l71. There was no change in mean serum
creatinine levels. We found no evidence of accumulated
Colomycin toxicity. The four patients were observed over a
further 6 to 17 i.v. courses and no significant rise in serum
urea or creatinine was seen. Mean admission and discharge
levels for all 53 study patients over an average of seven
further treatments was 4.0 and 4.7mmol l71 for urea and 71
and 69mmol l71 for creatinine. Although in response to
direct questioning most patients reported some experience
of dizziness, numbness, tingling, unsteadiness or muscle
weakness, except in one case all these symptoms were minor
and well tolerated. Moreover we found no clinically
significant non-neurological events (25). A subsequent
retrospective study of intravenous Colomycin use in adult
patients with CF in Liverpool has confirmed its good safety
profile (26).
Colomycin is eective in the treatment of CF respiratory
exacerbations. All the patients in our study showed
resolution of their acute infective exacerbation and
increases in respiratory function test results (25). Those
patients who received Colomycin and a second anti-
pseudomonal antibiotic showed the greater improvement
when compared to patients prescribed Colomycin alone,
the FEV1 rising by 18.5% vs. 9%. Other antibiotics used
were aztreonam, azlocillin, piperacillin, ceftazidime, imipe-
nem and ciprofloxacin. It was not possible to correlate the
greater improvement seen with combined therapy with any
particular additional antibiotic because of small patient
numbers. Comparison with statistics from our own general
clinical databank showed Colomycin alone resulted in gains
in respiratory function similar to conventional combined
antibiotic therapy, and that Colomycin in combination with
another antibiotic resulted in even greater improvement
suggesting a synergistic eect. The Liverpool retrospective
study, using Colomycin in combination with other intrave-
nous antibiotic wherever possible, also showed improve-
ment in all cases with significant increases in percentage
predicted FEV1 (26).
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We would recommend it as a second-line drug for patients
with multi-resistant P. aeruginosa. Because of its increasing
use, occasional Colomycin resistance has been seen. We
should therefore use it with care for the development of
widespread resistance would significantly limit our ther-
apeutic options.
The impact of Colomycin on the
management of cystic fibrosis—the
paediatrician’s viewpoint:
R. Dinwiddie
The primary pathogenic process in the lungs aected by CF
is one of early colonization and infection with various
pathogenic organisms. This initiates an intense inflamma-
tory response which persists throughout life. Early infection
with organisms such as S. aureus and Haemophilus
influenzae are major triggers of the inflammation, which is
a central feature of the long-term lung damage (69).
Once the lungs are infected, other organisms such as P.
aeruginosa are able to gain a foothold and contribute to the
pathogenic process.
Over a period of time this organism becomes a major
pathogen leading to lung damage. Any measure which can
inhibit or eradicate this process is central to prevention of the
progressive pulmonary damage which represents a major
challenge to the paediatrician advising on the child’s treatment.
The lungs of the CF infant are normal at birth but, in the
absence of treatment soon become infected (69). With oral
antibiotics, either given continuously or when cultures are
positive, chronic infection with S. aureus and H. influenzae
can be avoided, but P. aeruginosa sooner or later grows
from the respiratory cultures. Prior to the use of nebulized
Colomycin and the availability of oral ciprofloxacin in the
mid 1980s, early colonization with P. aeruginosa was
treated with i.v. anti-pseudomonal antibiotics only if the
infection was symptomatic—unfortunately, with this pol-
icy, chronic infection usually followed.
The early treatment of P. aeruginosa with nebulized
Colomycin and oral ciprofloxacin (19,20) has become an
important and successful component of paediatric manage-
ment which significantly reduces morbidity, reducing or
avoiding chronic infection in over 80% of patients. If the
organism persists after this it may be necessary to continue
this regime for 3 months. This can significantly delay the
recurrence of P. aeruginosa for up to 18 months (20).
When P. aeruginosa infection is persistent, then a 2-week
course of i.v. antibiotics is indicated (50). Long-term
administration of nebulized Colomycin is then recom-
mended with further courses of I.V. antibiotics either at 3-
monthly intervals or when respiratory symptoms and signs
indicate clinical deterioration. It is important to culture
respiratory secretions at 4–8 week intervals to identify
organisms and monitor their sensitivity.
Nebulized Colomycin has been used in our paediatric CF
clinic for a considerable number of years and the overall
emergence of resistance has been low. In fact, resistance ofP. aeruginosa to Colomycin is so rare that such a report
should always raise the possibility of the supposed P.
aeruginosa being B. cepacia or some other organism.
The use of increasingly frequent courses of i.v. antibiotics
over a period of several years does eventually lead to the
emergence of resistant organisms. Since Colomycin appears
to maintain its ecacy over a long period, in recent times it
has been used increasingly as an intravenous agent. More
recent favourable clinical experience in children (58) and
studies in adults with CF (25,26) have allayed previous
concerns about systemic toxicity.
Thus, in paediatric practice, Colomycin has proved to be
an eective agent for the treatment of early P. aeruginosa
colonization/infection in combination with oral ciproflox-
acin, significantly delaying or preventing the onset of
chronic infection. Longer term it is a useful suppressive
agent in children who are already chronically infected with
P. aeruginosa. It has also proved a useful and safe addition
to the range of agents available for intravenous use when
resistance to the more commonly used anti-pseudomonal
antibiotics becomes a problem.
The impact of Colomycin on the
management of cystic fibrosis—the
nurse manager’s viewpoint:
F. Duncan-skingle
Colomycin for nebulization came into use in the 1980s:
patients who had been taking two nebulized antibiotics, in
an eort to avoid antibiotic resistance, were now able to
have monotherapy. It was a drug rarely used intravenously,
and there was also a reduced risk of resistant organisms. A
positive advantage for patients was the taste, which was
infinitely more palatable than some of the previous
antibiotics used. Some of the drugs tasted unpleasant, but
patients persevered, convinced of the advantage to their
health. It can be dicult, or impossible, to discontinue
nebulized antibiotics with some patients: they are convinced
that it is the nebulized antibiotic that is keeping them well
and out of hospital. Many patients will increase the
prescribed dose from twice a day to three times, especially
if they are unwell, in a bid to keep out of hospital, and
many times they will succeed. People with CF are always
hopeful that they will reduce their admissions into hospital,
and also try to avoid i.v. antibiotics at home.
If the person with CF is busy at work, or going on
holiday, they may neglect their treatment, including
nebulized antibiotics, arguing lack of time. If they then
become ill, they are convinced of the positive indication for
the use of nebulized antibiotics. As one patient states
‘missing my nebulized Colomycin has an immediate eect.
However I can overcome this, by only missing one or two
doses. Otherwise it increases the amount of time and eort
needed to get back to my starting point’.
From a nursing perspective nebulized antibiotics are easy
to administer. The patient (or parent if a child) usually finds
the reconstitution of the antibiotic, and the use of the
nebulizer and compressor for administration, easy to learn.
638 J. M. LITTLEWOOD ET AL.Most patients tolerate nebulized antibiotics well. The biggest
chore for patients is the washing and drying of the equipment
every time it is used. This is essential to ensure that no
harmful pathogens are harboured in the wet nebulizer.
Patients have a ‘test dose’ of the prescribed nebulized
antibiotic, and respiratory function tests performed before
and after the first nebulized dose. This is to ensure that
there is no bronchial constriction, which can cause
discomfort and distress to the patient. If there is any
tightening in the chest it may be relieved by the use of
bronchodilators with the antibiotic.
In addition to its use in delaying chronic colonization
with P. aeruginosa, another important use for nebulized
Colomycin is in the pre- and postoperative management of
patients undergoing lung transplantation (70). It is usually
prescribed for a period of 6 months via a face-mask, to clear
the upper airways of Pseudomonas. There is some thought
that it should be given for longer, even for life. Patients with
multi-resistant P. aeruginosa awaiting transplant commonly
convert to sensitive strains when treated with nebulized
Colomycin (70).
There is no doubt that nebulized Colomycin has played a
vital part in reducing the decline of respiratory function and
therefore the number of hospital admissions for people with
CF (21). Hospitalization is costly and can be depressing for
young people; it also interferes with their lifestyle, and
increases the risk of cross infection. In summary, nebulized
Colomycin is eective treatment for early infection with P.
aeruginosa (20), can maintain respiratory function in
chronically infected patients, and reduce the incidence of
infection after transplantation. It is easy to reconstitute and
well tolerated by most patients.
The next ten years—future challenges:
J. M. Littlewood
Over the past 20 years, advances in the understanding of the
pathogenesis and treatment of have resulted in impressive
improvements in the health, quality and length of life of
people who have cystic fibrosis. There is no reason why
improvements should not continue over the next 10 years. In
the worst scenario, even if new pharmacological or gene
replacement strategies to improve CFTR function do not
become generally available, treatment to prevent and/or
eradicate early respiratory infection with S. aureus, P.
aeruginosa and whatever other organisms emerge as im-
portant pathogens, should permit most people with CF to
remain free of chronic respiratory infection and the
associated progressive decline in respiratory function for
many years.
The realization that early respiratory infection, particu-
larly with P. aeruginosa, can be treated and eradicated and
that chronic chest infection is not inevitable, is a relatively
recent but now well-established concept in many CF
centres—but surprisingly not all.
If all infants with CF are to be diagnosed before the
chronic infection is established and nutrition compromised,
very early diagnosis by neonatal screening is essential.Unfortunately, where neonatal screening is not routine,
some infants still suer irreversible pulmonary damage
before the diagnosis is eventually made. The early recogni-
tion of the infant who has CF and the careful monitoring,
eective treatment and eradication of respiratory pathogens
will remain a central component of CF management.
Nebulized antibiotics active against P. aeruginosa, delivered
directly to the patient’s airways, are now established as a
major component of such treatment. Colomycin, delivered
directly to the airways, has proved particularly valuable in
both the early eradication and later stabilization of P.
aeruginosa infection. The rarity of bacterial resistance and
the fact the drug is not a first line choice for i.v. treatment
(although useful in patients with resistant organisms) is an
added advantage.
To achieve the best results, all patients must continue to
have the advantage of adequate regular contact with the
professional team at a major specialist CF centre. At
specialist CF centres the sta continually strive to improve
existing treatments and evaluate their results; no present
day treatment is regarded as ‘established’ and beyond
improvement. They recognize and deal with the constant
changes required in management as new pathogens emerge:
at times, it must be said, as a result of very successful
present treatments, for example the increasing prevalence of
Stenotrophomonas maltophilia and Aspergillus fumigatus as
P. aeruginosa is successfully eradicated. If new hoped-for
novel treatments to correct or improve CFTR function are
introduced within the next decade, as is likely, the
conventional antibiotic treatments should be considerably
more eective but will still be required to some extent.
Over the past decade, Colomycin has re-emerged as the first
choice antibiotic for nebulized treatment of both early and
chronic P. aeruginosa in people with CF. It is also a valuable
addition to the i.v. antibiotics used when the organism
becomes resistant to the more frequently used drugs. Its
particular characteristics, as described in this review, suggests
that it will continue to have an important role in the treatment
of people with CF during the next decade.
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